
The EU has granted marketing authorisation (MA) for Filspari – CSL Vifor and Travere Therapeutics’ therapy for primary IgA nephropathy …
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions

